GlassScriptPhysician profile
Michael J Hyman
NPI 1487642492
$5,171.69
in general payments reported to CMS, 2019-2025
40 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $913 · 2021: $349 · 2022: $1,248 · 2023: $819 · 2024: $656 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $658.93 | 2020-2022 | |
| Neotract INC. | $616.21 | 2020 | |
| Blue Earth Diagnostics | $365.83 | 2020-2025 | Posluma |
| Abbvie INC. | $310.36 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $289.58 | 2021-2025 | Prolaris, Myrisk |
| Pfizer INC. | $284.44 | 2019-2025 | |
| Teleflex LLC | $271.43 | 2022-2025 | Barrigel, Urolift |
| Endo Pharmaceuticals INC. | $234.56 | 2019-2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $234.53 | 2022-2025 | |
| Astellas Pharma US INC | $159.23 | 2019-2024 | Xtandi |
| Antares Pharma, INC. | $154.62 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Boston Scientific Corporation | $148.55 | 2019-2025 | Ams 700, Rezum Generator |
| Procept Biorobotics Corporation | $116.91 | 2022 | |
| Endo USA, INC. | $104.66 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $98.26 | 2019-2025 | Adstiladrin |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $93.69 | 2023 | |
| Janssen Biotech, INC. | $83.59 | 2021-2025 | Erleada |
| 180 Medical, INC. | $78.05 | 2020-2024 | Bardex I.C. Tiemann Model Coude Tip Foley Catheter |
| Azurity Pharmaceuticals, INC. | $73.53 | 2025 | Azmiro |
| Urogen Pharma, INC. | $73.02 | 2023-2024 | Jelmyto |
| Kerecis Limited | $70.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sumitomo Pharma America, INC. | $69.13 | 2023-2025 | Gemtesa |
| Immunitybio, INC. | $68.25 | 2025 | |
| Convatec INC. | $66.30 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $56.46 | 2025 | |
| Laborie Medical Technologies Corp. | $48.40 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Olympus America INC. | $48.34 | 2020-2023 | Itind System |
| Dendreon Pharmaceuticals LLC | $44.98 | 2019-2020 | |
| Myovant Sciences INC. | $36.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.41 | 2024 | |
| Acerus Pharmaceuticals Corporation | $30.95 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $26.43 | 2023 | Bard Urinary Drainage Bag |
| Halozyme INC | $24.73 | 2023 | |
| Metuchen Pharmaceuticals | $24.13 | 2019 | |
| Medtronic USA, INC. | $20.97 | 2020 | |
| Allergan, INC. | $19.38 | 2019 | |
| Axonics, INC. | $17.50 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $16.93 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.45 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.